1. Home
  2. MDWD vs ONDS Comparison

MDWD vs ONDS Comparison

Compare MDWD & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • ONDS
  • Stock Information
  • Founded
  • MDWD 2000
  • ONDS 2014
  • Country
  • MDWD Israel
  • ONDS United States
  • Employees
  • MDWD N/A
  • ONDS N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • ONDS Telecommunications Equipment
  • Sector
  • MDWD Health Care
  • ONDS Telecommunications
  • Exchange
  • MDWD Nasdaq
  • ONDS Nasdaq
  • Market Cap
  • MDWD 184.8M
  • ONDS 218.8M
  • IPO Year
  • MDWD 2014
  • ONDS N/A
  • Fundamental
  • Price
  • MDWD $20.15
  • ONDS $1.69
  • Analyst Decision
  • MDWD Strong Buy
  • ONDS Buy
  • Analyst Count
  • MDWD 1
  • ONDS 1
  • Target Price
  • MDWD $25.00
  • ONDS $4.00
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • ONDS 5.9M
  • Earning Date
  • MDWD 03-20-2025
  • ONDS 03-31-2025
  • Dividend Yield
  • MDWD N/A
  • ONDS N/A
  • EPS Growth
  • MDWD N/A
  • ONDS N/A
  • EPS
  • MDWD N/A
  • ONDS N/A
  • Revenue
  • MDWD $19,720,000.00
  • ONDS $8,024,937.00
  • Revenue This Year
  • MDWD $10.15
  • ONDS N/A
  • Revenue Next Year
  • MDWD $25.62
  • ONDS $279.95
  • P/E Ratio
  • MDWD N/A
  • ONDS N/A
  • Revenue Growth
  • MDWD N/A
  • ONDS N/A
  • 52 Week Low
  • MDWD $11.04
  • ONDS $0.54
  • 52 Week High
  • MDWD $24.00
  • ONDS $3.40
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 57.75
  • ONDS 44.00
  • Support Level
  • MDWD $18.73
  • ONDS $1.50
  • Resistance Level
  • MDWD $19.73
  • ONDS $1.84
  • Average True Range (ATR)
  • MDWD 0.78
  • ONDS 0.20
  • MACD
  • MDWD 0.02
  • ONDS -0.09
  • Stochastic Oscillator
  • MDWD 66.35
  • ONDS 19.79

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About ONDS Ondas Holdings Inc.

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

Share on Social Networks: